Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology
Link
http://link.springer.com/article/10.1007/s00345-018-2264-0/fulltext.html
Reference27 articles.
1. Gill DM, Agarwal N (2017) Cancer immunotherapy: a paradigm shift in the treatment of advanced urologic cancers. Urol Oncol Semin Orig Investig 35:676–677. https://doi.org/10.1016/j.urolonc.2017.09.023
2. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143–e152. https://doi.org/10.1016/S1470-2045(17)30074-8
3. Siefker-Radtke A, Curti B (2017) Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nat Rev Urol. https://doi.org/10.1038/nrurol.2017.190
4. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S et al (2017) Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 23:1920–1928. https://doi.org/10.1158/1078-0432.CCR-16-1741
5. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214
Cited by 71 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Splenic Pseudoprogression After CAR-T Therapy Detected by 18F-FDG PET/CT in a Refractory Diffuse Large B-Cell Lymphoma Patient;Clinical Nuclear Medicine;2024-04-05
2. Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications;Cancer Cell International;2024-03-12
3. Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma;Journal of Clinical Medicine;2024-01-05
4. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group;Journal of Clinical Oncology;2023-12-10
5. Hyperprogression after anti-programmed death-1 therapy in a patient with urothelial bladder carcinoma: A case report;World Journal of Clinical Cases;2023-10-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3